CU6 - Media and Industry News, page-459

I know prior data has shown you prolonged OS flots, but I'm concerned about the rPFS on the recent trial results. This is fairly similar to pluvicto?

Once lesions start to grow(end of rPFS), it means that the drug has stopped being effective(or at least blunted). Normally, I believe in most instances, rPFS and OS have a correlation. This may not be the case for fractionated lu177, but you're sort of betting against the norm.

with bisPSMA, you're effectively doubling the amount of dose you're getting into the cancer, at a similar dosage to 177lu, and they're now dosing at a higher dose(AT explaining that pluvicto could have in fact been dosed higher). Due to the half life of Cu67, you can also dose at a more frequent rate ie higher dose and quicker, which logically should give better results. Like most therapies, radiation is dose dependent, so more you give, the more you can kill.

i still hope tlx591 has a positive response, but I have a few concerns about it.